These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 25117168)

  • 1. Delayed onset perforating folliculitis associated with sorafenib.
    Batalla A; Menéndez L; Blay P; Curto JR
    Australas J Dermatol; 2014 Aug; 55(3):233-5. PubMed ID: 25117168
    [No Abstract]   [Full Text] [Related]  

  • 2. Perforating folliculitis-like reaction related to sorafenib.
    Eberst E; Rigau V; Pageaux GP; Guillot B; Kluger N
    Cutis; 2014 Jan; 93(1):E8-10. PubMed ID: 24505595
    [No Abstract]   [Full Text] [Related]  

  • 3. Sorafenib induced eruptive melanocytic lesions.
    Uhlenhake EE; Watson AC; Aronson P
    Dermatol Online J; 2013 May; 19(5):18184. PubMed ID: 24011281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Case of Pancreatic Side Effects Resulting from Sorafenib and Axitinib Treatment of Stage IV Renal Cell Carcinoma.
    Kitamura Y; Yoshii H; Nishimoto K; Shinchi Y; Tokonabe S; Takao M; Daido Y
    Keio J Med; 2015; 64(4):62-4. PubMed ID: 26727578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pneumatosis intestinalis and hepatic portal venous gas in a patient receiving sorafenib.
    Kashima T; Ohno Y; Tachibana M
    Int J Urol; 2012 Nov; 19(11):1041-2. PubMed ID: 22788573
    [No Abstract]   [Full Text] [Related]  

  • 6. Sorafenib-induced eruptive melanocytic lesions.
    Kong HH; Sibaud V; Chanco Turner ML; Fojo T; Hornyak TJ; Chevreau C
    Arch Dermatol; 2008 Jun; 144(6):820-2. PubMed ID: 18559790
    [No Abstract]   [Full Text] [Related]  

  • 7. Transient perforating folliculitis induced by sorafenib.
    Minami-Hori M; Ishida-Yamamoto A; Komatsu S; Iiduka H
    J Dermatol; 2010 Sep; 37(9):833-4. PubMed ID: 20883372
    [No Abstract]   [Full Text] [Related]  

  • 8. [Side effects of sorafenib and countermeasures].
    Nakayama M; Arai Y; Nishimura K
    Hinyokika Kiyo; 2012 Nov; 58(11):635-7. PubMed ID: 23254792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib-induced annular pustular psoriasis (Milian-Katchoura type).
    Du-Thanh A; Girard C; Pageaux GP; Guillot B; Dereure O
    Eur J Dermatol; 2013; 23(6):900-1. PubMed ID: 24184416
    [No Abstract]   [Full Text] [Related]  

  • 10. Case of sorafenib-induced thyroid storm.
    Haraldsdottir S; Li Q; Villalona-Calero MA; Olencki TE; Kendra K; Ing SW
    J Clin Oncol; 2013 Jun; 31(16):e262-4. PubMed ID: 23610115
    [No Abstract]   [Full Text] [Related]  

  • 11. Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma.
    İlknur T; Akarsu S; Çarsanbali S; Lebe B; Fetil E
    J Drugs Dermatol; 2014 Aug; 13(8):899-900. PubMed ID: 25116964
    [No Abstract]   [Full Text] [Related]  

  • 12. Grade III hand-foot skin reaction induced by sorafenib.
    Chiriac A; Coros MF; Podoleanu C; Stolnicu S
    An Bras Dermatol; 2017; 92(4):590-591. PubMed ID: 28954127
    [No Abstract]   [Full Text] [Related]  

  • 13. Sorafenib-Induced Eruption Mimicking Erythema Multiforme.
    Pichard DC; Cardones AR; Chu EY; Dahut WL; Kong HH
    JAMA Dermatol; 2016 Feb; 152(2):227-8. PubMed ID: 26422655
    [No Abstract]   [Full Text] [Related]  

  • 14. Multiple squamous cell carcinomas following treatment with sorafenib for renal cell carcinoma.
    El Tal AK; Remichofsky CJ; Mehregan DA; Ganger LK
    Int J Dermatol; 2013 Dec; 52(12):1538-41. PubMed ID: 23676092
    [No Abstract]   [Full Text] [Related]  

  • 15. Acne inversa-like lesions associated with the multi-kinase inhibitor sorafenib.
    Pichler M; Carriere C; Mazzoleni G; Kluge R; Eisendle K
    Clin Exp Dermatol; 2014 Mar; 39(2):232-3. PubMed ID: 24330088
    [No Abstract]   [Full Text] [Related]  

  • 16. Hyperthyroidism and thyroid autoimmunity induced by sorafenib in metastatic renal cell cancer.
    Konca Degertekin C; Coşkun U; Baloş Törüner F; Aktürk M; Demirci U
    Endocrine; 2012 Dec; 42(3):756-7. PubMed ID: 22562706
    [No Abstract]   [Full Text] [Related]  

  • 17. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
    Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
    Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT study.
    Jäger D; Ma JH; Mardiak J; Ye DW; Korbenfeld E; Zemanova M; Ahn H; Guo J; Leonhartsberger N; Stauch K; Böckenhoff A; Yu J; Escudier B
    Clin Genitourin Cancer; 2015 Apr; 13(2):156-64.e1. PubMed ID: 25444666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib.
    Szmit S; Zaborowska M; Waśko-Grabowska A; Żołnierek J; Nurzyński P; Filipiak KJ; Opolski G; Szczylik C
    Kidney Blood Press Res; 2012; 35(6):468-76. PubMed ID: 22688785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma.
    Ikeda M; Fujita T; Amoh Y; Mii S; Matsumoto K; Iwamura M
    Urol Int; 2013; 91(4):482-3. PubMed ID: 23969404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.